NDATOPICALSOLUTION
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
JUBLIA (efinaconazole) by Bausch + Lomb. Approved for azole antifungal [epc]. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUBLIA (efinaconazole) is a topical azole antifungal solution approved by the FDA in June 2014 for the treatment of onychomycosis (fungal nail infections). The drug works by inhibiting fungal lanosterol 14α-demethylase, an enzyme essential for ergosterol biosynthesis in fungal cell membranes, thereby disrupting fungal cell membrane integrity. JUBLIA demonstrates in vitro activity against common causative organisms including Trichophyton rubrum and Trichophyton mentagrophytes, with minimum inhibitory concentrations of 0.06 mcg/mL or less against at least 90% of isolates.
$0.1BPart D
9.0 years to LOEMechanism of Action
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
Started Nov 2017
97 enrolled
Mild to Moderate Onychomycosis Due to Dermatophyte
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Started Aug 2016
62 enrolled
Onychomycosis
Career Relevance
JUBLIA generates employment opportunities for brand managers focused on dermatology/specialty care, field sales representatives targeting dermatologists and podiatrists, and medical science liaisons educating prescribers on fungal nail treatment pathways. Key skills for team members include understanding topical antifungal pharmacology, onychomycosis epidemiology and treatment paradigms, formulary management, and competitive positioning against systemic alternatives. Currently, zero open positions are linked to this product in available job tracking data.
Worked on JUBLIA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.